Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers ...

Introducing DeepMerkel: a machine-learning model that delivers personalized survival predictions for Merkel cell carcinoma, ...

A recent study has made significant strides in uncovering how the oral microbiome, particularly the bacterium Fusobacterium ...

Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

Epigenetic modifiers, enzymes that catalyze covalent modifications on chromatin, play a pivotal role in establishing stable ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and ...

Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, has historically presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, ...